Week in Review: China Leads Emerging Countries Pharma M&A
Spending on pharmaceutical M&A deals is up 67% in emerging markets this year, and China, with one-third of the activity, leads the pack; Sinopharm and China Development Bank signed a $6.4 billion agreement to help Sinopharm expand and modernize; Fosun Pharma and Dalian Wanchun Biotech will establish a JV to develop innovative oncology treatments; the Shanghai Institute of Biochemistry and Cell Biology is collaborating with MRC Technology of the UK to develop new drug targets; Jiangxi Boya Bio-Pharma will pay up to $18.5 million to purchase a 68% stake in Zhejiang Haikang Biologicals; DelMar Pharma of Vancouver talked to ChinaBio® Today about its partnership with Guangxi Wuzhou Pharma on a cancer treatment; Mauna Kea Technologies was granted SFDA approval to market its probe-based microscope, Cellvizio®, in China; and Veridex, a Johnson & Johnson company, received SFDA approval for CellSearch, an in vitro diagnostic device that tests for circulating tumor cells in the bloodstream. More details…. Stock Symbols: (SHA: 600196; HK: 2196) (SHA: 300294) (EN: MKEA) (NYSE: JNJ) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here